We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-7.4%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.38B
AUM Growth
-$480M
Cap. Flow
+$130M
Cap. Flow %
2.42%
Top 10 Hldgs %
41.73%
Holding
224
New
23
Increased
133
Reduced
36
Closed
13

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$23.8M
2
GKOS icon
Glaukos
GKOS
+$20.8M
3
ARVN icon
Arvinas
ARVN
+$19.8M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$18.4M
5
PACB icon
Pacific Biosciences
PACB
+$13.3M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$72.6M
2
GILD icon
Gilead Sciences
GILD
+$33.8M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$23.2M
4
TDOC icon
Teladoc Health
TDOC
+$19.5M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.28%
2 Industrials 0.53%
3 Technology 0.51%
4 Financials 0.07%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$499M 9.27%
8,321,914
+364,786
+5% +$23.8M
NBIX icon
2
Neurocrine Biosciences
NBIX
$17.2B
$297M 5.53%
3,298,474
-247,970
-7% -$23.2M
INCY icon
3
Incyte
INCY
$23.4B
$274M 5.1%
3,696,200
-1,450
-0% -$117K
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$123B
$242M 4.5%
1,429,139
+8,650
+0.6% +$1.53M
SAGE
5
DELISTED
Sage Therapeutics
SAGE
$183M 3.4%
1,303,504
-17,900
-1% -$2.99M
RDUS
6
DELISTED
Radius Health, Inc.
RDUS
$177M 3.29%
6,876,885
+36,100
+0.5% +$885K
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$35.7B
$158M 2.94%
1,965,072
+37,678
+2% +$2.98M
ESPR
8
DELISTED
Esperion Therapeutics
ESPR
$155M 2.89%
4,241,461
+184,050
+5% +$7.29M
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$134M 2.49%
1,366,528
+25,100
+2% +$2.83M
HALO icon
10
Halozyme
HALO
$9.23B
$124M 2.31%
8,014,356
-233,504
-3% -$3.85M
AGIO icon
11
Agios Pharmaceuticals
AGIO
$2.36B
$116M 2.15%
3,571,554
+443,420
+14% +$18.4M
ARGX icon
12
argenx
ARGX
$53.8B
$110M 2.05%
973,239
+28,600
+3% +$3.87M
CELG
13
DELISTED
Celgene Corp
CELG
$108M 2%
1,085,600
-764,400
-41% -$72.6M
ISRG icon
14
Intuitive Surgical
ISRG
$122B
$94.8M 1.76%
526,935
+21,489
+4% +$3.72M
ABT icon
15
Abbott
ABT
$175B
$91.9M 1.71%
1,098,114
+140,519
+15% +$11.9M
MDT icon
16
Medtronic
MDT
$106B
$87.7M 1.63%
807,638
+28,227
+4% +$2.95M
ALDR
17
DELISTED
Alder Biopharmaceuticals
ALDR
$84.7M 1.58%
4,492,466
+373,660
+9% +$4.27M
TDOC icon
18
Teladoc Health
TDOC
$1.7B
$77.1M 1.43%
1,139,057
-295,955
-21% -$19.5M
MRNA icon
19
Moderna
MRNA
$24.5B
$77.1M 1.43%
4,844,081
+119,835
+3% +$1.77M
ELV icon
20
Elevance Health
ELV
$80.9B
$73.5M 1.37%
306,106
-54,633
-15% -$15M
EXEL icon
21
Exelixis
EXEL
$14.1B
$68.2M 1.27%
3,858,700
-20,100
-0.5% -$407K
MYOK
22
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$67.4M 1.25%
1,292,513
+27,600
+2% +$1.47M
MGNX icon
23
MacroGenics
MGNX
$285M
$65.4M 1.22%
5,125,564
+730,300
+17% +$10.5M
ILMN icon
24
Illumina
ILMN
$28.2B
$63.1M 1.17%
213,137
-21,443
-9% -$6.32M
HUM icon
25
Humana
HUM
$48B
$62M 1.15%
242,673
+1,461
+0.6% +$410K
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2019 Portfolio in Review

As of Q3 2019, Bellevue Group held 224 positions worth $5.38B, down 8.2% from $5.86B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group's Q3 2019 filing shows 23 new, 133 increased, 36 reduced and 13 closed positions. Its largest new stake was Arvinas: 806,403 shares worth $17.4M. The largest sale was Celgene Corp, an estimated $72.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2019 buy was Arvinas: 806,403 shares worth $17.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2019, an estimated $23.8M increase.
  • Bellevue Group's biggest Q3 2019 reduction was Celgene Corp, cutting an estimated $72.6M.
  • Bellevue Group fully exited Avedro, Inc Common Stock in Q3 2019, selling an estimated $15.8M.
  • Bellevue Group's ten largest holdings make up 42% of its $5.38B portfolio in Q3 2019.
  • Bellevue Group opened 23 new positions and closed 13 in Q3 2019.
  • Bellevue Group's portfolio value fell 8.2% quarter-over-quarter to $5.38B.

Based on Bellevue Group's 13F filing for Q3 2019, filed 14 Nov 2019.